HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarins results

This article was originally published in The Rose Sheet

Executive Summary

Group net income was $35.2 mil. (€1=$1.23) in the first half versus a loss of $7.8 mil. a year ago, French firm reports Sept. 9. Profitability is attributable to "sustained sales growth combined with strict control over non-productive expenses," Clarins says. Net earnings excluding couture were up 3.5%, or 17.9% on a like-for-like basis, to $34.7 mil. Operating income increased 13.3%, or 21.7% like-for-like, to $61 mil. Clarins reported first half sales in July; revenue grew 4.6%, or 7.8% like-for-like, to $526.8 mil. (€1=$1.20) (1"The Rose Sheet" Aug. 2, 2004, p. 4)...

You may also be interested in...



Clarins Freshens Up Super Restorative With Eye Concentrate, Cream

Clarins is expanding its Super Restorative franchise in January with Total Eye Concentrate and Day Cream SPF 20, the French firm said

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

UsernamePublicRestriction

Register

RS012437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel